Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Topic or Issue
Home Search/Browse Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, 2015 ASCO Annual Meeting (May 29 - June 2, 2015).
Vol 33, No 15_suppl (May 20 Supplement), 2015: 3069
© 2015 American Society of Clinical Oncology
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, J.
Right arrow Articles by Sourdive, D.
Right arrow Search for Related Content
Right arrow Articles by Smith, J.
Right arrow Articles by Sourdive, D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Delicious   Add to Digg  
What's this?

UCART19, an allogeneic "off-the-shelf" adoptive T-cell immunotherapy against CD19+ B-cell leukemias.

Julianne Smith, Laurent Poirot, Brian Philip, Cecile Schiffer-Mannoui, Sophie Derniame, Hong Zhan, Sian Stafford, Stephan Reynier, Sylvain Arnould, Agnes Gouble, Waseem Qasim, Karl Peggs, Martin Pule and David Sourdive

Cellectis, Paris, France; University College London, London, United Kingdom

Abstract Disclosures



Background: Autologous T-cells engineered to express chimeric antigen receptors (CARs) that target specific tumor antigens are of high potential in treating different kinds of cancer. However, they must be generated on a "per patient" basis, thereby limiting the population of patients that could benefit from this approach. Methods: We have developed a standardized platform for manufacturing T-cells from third-party healthy donors to generate allogeneic "off-the-shelf" engineered CD19-CAR+ T-cell–based frozen products. Our platform involves the use of transcription activator-like effector nucleases (TALEN), which mediate the simultaneous inactivation of two genes through genome editing. The knockout of the TCR alpha gene eliminates TCR expression and is intended to abrogate the donor T-cell’s potential for graft-versus-host disease (GvHD), while knocking out the CD52 gene makes donor T-cells resistant to the lymphodepleting agent alemtuzumab. In addition, our T-cells are engineered to co-express the RQR8 gene as a safety feature, with the aim of rendering them sensitive to the monoclonal antibody rituximab. Results: We have obtained proof-of-concept by manufacturing TCR/CD52-deficient RQR8+ and CD19-CAR+ T-cells (UCART19) using a good manufacturing practice–compatible process and have demonstrated that UCART19 cells were functional using in vitro assays. Furthermore, we have demonstrated that the ability of UCART19 cells to engraft into an orthotopic human CD19+ lymphoma xenograft immunodeficient mouse model. UCART19 cells exhibited antitumor activity equivalent to that of standard CD19 CAR T-cells. We also demonstrated that UCART19 cells did not mediate alloreactivity in a xeno-GvHD mouse model. Finally, the effectiveness of the rituximab-induced depletion mechanism of RQR8+cells was shown in an immunocompetent mouse model. Conclusions: This valuable dataset supports the development of allogeneic CAR T-cells, and UCART19 will be investigated in an exploratory, first-in-human, clinical trial where refractory/relapsed CD19+ B-cell leukemia patients are to be enrolled.

 Librarians &
 Rights &

Copyright © 2015 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
HighWire Press HighWire Press™ assists in the publication of JCO Online